Epacadostat
As of the edition of 20 October 2026, Epacadostat is a small molecule: stopped in 2024; acts on IDO1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2024
- Kind
- Small molecule
- Registered trials
- 58, 27 stopped early
- Disease areas
- Cancer; Lungs and airways; Urinary and reproductive; Digestive system; Pregnancy and women's health; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
4 companies on route A because of this drug.
Companies on route A for this drug
In the product4 companies are on route A because of Epacadostat.
See the 4 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| IDO1 | Indoleamine 2,3-dioxygenase 1 | P14902 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 11 | 5 | 0 | 5 |
| Phase 2 | 40 | 16 | 2 | 20 |
| Phase 3 | 7 | 5 | 0 | 2 |
| All trials | 58 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Incyte | Lead sponsor of trials | 2010 to now |
| Novartis | Lead sponsor of trials | 2016 to now |
| ImmunoVaccine Technologies | Lead sponsor of trials | 2016 to now |
| Merck & Co. | Lead sponsor of trials | 2016 to now |